Fruquintinib accepted for review by EMA

The European Medicines Agency (EMA) has validated and accepted for regulatory review the marketing authorization application (MAA) for fruquintinib.

Under development by Japanese pharma major Takeda (TYO: 4503) and China-based Hutchmed (AIM: HCM, HKEX:13), fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

If approved, fruquintinib will be the first and only highly selective inhibitor of all three VEGF receptors approved in the European Union for previously treated metastatic CRC.